Form 4: Denali Therapeutics Director Vicki L. Sato Sells Shares Under 10b5-1 Trading Plan

Director Vicki L. Sato sold 1,674 shares of Denali Therapeutics Inc. (DNLI) common stock at a price of $20.39 per share on May 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 15, 2024, Vicki L. Sato, a director of Denali Therapeutics Inc., sold 1,674 shares of common stock.
• The sale was executed at a price of $20.39 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on September 27, 2023.
• Following the transaction, Sato beneficially owns 116,369 shares of Denali Therapeutics Inc., which includes 4,216 unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale under a pre-arranged trading plan, which is neither particularly positive nor negative.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices.

Comparison to Industry Standards

• Insider sales are a regular part of corporate governance, and the use of 10b5-1 plans is a standard practice among executives and directors at publicly traded companies like Denali Therapeutics.
• Comparable companies such as Biogen, Amgen, and Regeneron also see regular insider trading activity, often under similar pre-arranged trading plans.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 trading plan mitigates concerns about insider information being used.

Key Dates